OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

Charity registration number :1194608

Company registration number CE025306 (England and Wales)

THE CANCER TREATMENT AND RESEARCH TRUST CIO ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

CONTENTS

Page
Trustees report 1 - 10
Independent examiner's report 11
Statement of financial activities 12
Balance sheet 13 - 14
Notes to the financial statements 15 - 22

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

STRUCTURE, GOVERNANCE, MANAGEMENT

The history of the charity goes back to 1985. The charity supports work mainly in the departments of medical oncology at the West London Cancer Centre based at Charing Cross and Hammersmith Hospitals (Imperial College Healthcare NHS Trust) and in the department of medical oncology at the Mount Vernon Cancer Centre, in Northwood, Middlesex. The charity has been controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Trustees

The CTRT Board of Trustees is made up of 10 professionals with legal or medical backgrounds as regulated by the deed of trust in line with the Charity Commission regulations. Cancer physicians dominate, in line with the aims of the charity.

Administration

On 1st January 2022, CTRT officially transitioned to a Charitable Incorporated Organisation (CIO) status. The original Cancer Treatment and Research Trust (charity number 292909) remains registered as a charity with the Charity Commission, albeit it only remains active in order to manage any residual matters following the 2022 transition.

OBJECTIVES AND ACTIVITIES

The Cancer Treatment and Research Trust (CTRT) which was founded in 1985, supports work mainly in the departments of medical oncology at the West London Cancer Centre based at Charing Cross Hospital and in the department of medical oncology at the Mount Vernon Cancer Centre, in Northwood, Middlesex. The CTRT exists to support treatment and research into many forms of malignant disease and has been particularly involved in understanding how certain cancers develop, finding better ways to monitor them and developing new anti-cancer agents. It remains committed to funding research that is not adequately funded either by the major cancer charities such as CRUK, the MRC or the pharmaceutical industry.

ACHIEVEMENT AND PERFORMANCE

The trustees are pleased with the achievements and performance of the Trust in 2023. In 2023, research, either fully or partly funded by CTRT, led to 84 publications.

The research supported by CTRT can be roughly split into the following areas:

Details about the research, together with the relevant publications and studies, are available on the Trust’s website - cancertreatment.org.uk

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

The financial results for the year are as shown in the financial section of this report and cover accounting period of 12 months from 01 January 2023 to 31st December 2023. The carry forward funds as at 31st December 2023 amounted to £1,185,469, of which was £899,920 was unrestricted and £285,549 was restricted.

PLANS FOR THE FUTURE

Investing in fundraising:

CTRT have agreed to recruit a second part time staff member who will have responsibility for communications and marketing of the charity with the aim of increasing the charity’s supporter base.

Plans for research:

CTRT will continue to support a diverse variety of research into many cancers including several different types of less common cancers such as ovarian, uterine, melanoma and also very rare cancers such as gestational trophoblast disease, germ cell tumours and rare gynaecological cancers. Our research supports clinical studies as well as laboratory focused work such as developing novel biomarkers. Immunotherapy continues to be a major area of interest in the cancer world and CTRT supports research studying the effects of immunotherapy in trophoblastic, lung and renal cancers.

Details of previous research and further details about existing projects can be found on the website.

RISK MANAGEMENT

The Trustees are aware of the risks affecting the Trust and its work and have ensured that policies are in place to mitigate the effect of these risks.

Financial risks and Investment

A key aim of the Board is to ensure CTRT holds adequate reserves for working capital purposes and has sufficient funds to meet contractual liabilities and winding down costs, if the organisation were to close. This includes redundancy pay, amounts due to creditors and commitments under contracts. CTRT’s level of reserves also helps the organisation to plan expenditure against variations in the way funding is received. To balance the uncertainty of funding, our policy is to maintain financial reserves to cover these costs and allow for an orderly wind down. The current estimate of these costs is c £20,000 - £30,000. Without current level of support from our individual donors and based on current expenditure levels, CTRT is estimated to still remain in a position to cover these costs for the coming 12 months as our unrestricted reserve stand at about £899,920 .

Governance structure:

The review of governance structure, policies and procedures was commenced and following that review, any recommendations made and agreed upon by the trustees will be implemented in the authorised order.

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Reserves policy

Sufficient reserves are maintained to ensure that all expenses, as well as future research costs, are covered in the event no donations are received in any one year.

For many years the CTRT received funds to pay for research staff running clinical trials from pharmaceutical companies and trial organisations. Increasingly these funds have been paid directly to support the local NHS Trusts who employ these staff. As of 1st January 2008 the accounts related to Mount Vernon Cancer Centre only include income and expenses actually paid into or out of CTRT accounts.

CONCLUSION

Research, either totally or partly funded by CTRT led to 84 publications in 2023.

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees are confident that CTRT will continue to fund work that will lead to improvements in the detection, monitoring and treatment of cancer and care for patients with cancer.

REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number CE025306 (England and Wales)

Registered Charity number

1194608

Registered office

Upper East Research Office Mount Vernon Hospital Rickmansworth Road Northwood HA6 2RN

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees:

Professor Gordon Rustin Professor Michael Seckl Professor Marcia Hall Professor Paul Nathan Dr Anand Sharma Dr Andreas Polychronis Dr David Pinato Dr Ehsan Ghorani Kiran Grewal Russell Hallam

Statement of Trustees responsibilities

The trustees (who are also the directors of The Cancer Treatment And Research Trust CIO for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.In preparing those financial statements, the trustees are required to

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

Signed on behalf of the Trustees

12 February 2025

..................

Professor Michael Seckl- Trustee

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

INDEPENDENT EXAMINER'S REPORT

TO THE OF THE CANCER TREATMENT AND RESEARCH TRUST CIO

I report to the trustees on my examination of the financial statements of The Cancer Treatment and Research Trust CIO (‘the charity’) for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet and related notes.

This report is made solely to the charity’s trustees, as a body, in accordance with section 145 of the Charities Act 2011. My work has been undertaken so that I might state to the charity’s trustees those matters I am required to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for my work, for this report, or for the opinions I have formed.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (‘the Act’).

I report in respect of my examination of the charity’s financial statements carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently I express no opinion as to whether the financial statements present a ‘true and fair’ view and my report is limited to those specific matters set out in the independent examiner’s statement.

Independent examiner's statement

Since the CIO’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Andrew Millet BA MBA FCA

A fellow member of the Institute of Chartered Accountants in England and Wales. Millet Accountants Ltd Beyond Aldgate Tower 2 Leman Street Aldgate London E1 8FA

12 February 2025

Dated: .........................

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

Unrestricted
Restricted
funds
funds
2023
2023
Notes
£
£
Income from:
Donations and legacies
2
103,889
63,648
Investments
3
12,201
-
Total income
116,090
63,648
Expenditure on:
Raising funds
4
5,708
-
Charitable activities
5
78,392
96,539
Other expenditure
9
42,403
-
Total expenditure
126,503
96,539
Net income/(expenditure) and
movement in funds
(10,413)
(32,891)		 Total
Unrestricted
Restricted
funds
funds
2023
2022
2022
£
£
£
167,537
108,720
269,727
12,201
3,393
-
179,738
112,113
269,727
5,708
4,214
-
174,931
86,467
77,143
42,403
34,683
-
223,042
125,364
77,143
(43,304)
(13,251)
192,584		 Total
2022
£
378,447
3,393
381,840
4,214
163,610
34,683
202,507
179,333

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

BALANCE SHEET

AS AT 31 DECEMBER 2023

Unrestricted
Fund
Notes
£
Fixed assets
Intangible assets
11
1672
Tangible assets
12
625
Investments
13
6,469
8,766
Current assets
Debtors
14
4,196
Cash at bank and in hand
675,130
679,326
Creditors: amounts falling due within
one year
15
(11,661)
Net current assets
667,665
Total assets less current liabilities
676,431
Net assets
676,431
The funds of the Charity
Restricted income funds - general
Unrestricted funds - general		 2023
2022
Restricted
Fund
Total funds
Total funds
£
£
£
1,672
0
625
906
6,469
6,469
8,766
7,375
4,196
32,864
509,038
1,184,168
1,238,391
509,038
1,188,364
1,271,255
(11,661)
(49,855)
509,038
1,176,703
1,221,400
509,038
1,185,469
1,228,775
509,038
1,185,469
1,228,775
285,549
541,995
899,920
686,780
1,185,469
1,228,775

The notes on pages 17 to 22 form part of these financial statements.

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2023

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not deposited notice, pursuant to Section 476 of the Companies Act 2006 requiring an audit of these financial statements.

The trustees acknowledge their responsibilities for

(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and

(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been audited under the requirements of Section 145 of the Charities Act 2011.

The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by: 12 February 2025

..............................

Professor Michael Seckl-Trustee

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

1.1 Accounting convention

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

Going concern:

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the continue to adopt the going concern basis of accounting in preparing the financial statements.

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern

1.2 Charitable funds

1.3 Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and legacies are provided to the Charity, in order that the Charity can fulfil its purpose.

1.4 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

1.5 Investments

Fixed asset investments other than programme related investments, are included at market value at the balance sheet date,

Realised gains and losses on investments are calculated as the difference between sales proceeds and their market value at the start of the year, or their subsequent cost, and are charged or credited to the Statement of Financial Activities in the period of disposal.

Unrealised gains and losses represent the movement in market values during the year and are credited or charged to the Statement of Financial Activities based on the market value at the year end.

1.6 Intangible fixed assets other than goodwill

Website 10% on reducing balance

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.7 Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and equipment 25% on reducing balance Computer equipment 33% on reducing balance

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

The charity opted to adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

1.9 Financial instruments

The Charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10 Taxation

The charity is exempt from corporation tax on its charitable activities.

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies (Continued)

1.11 Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

1.12 Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2 Income from donations and legacies

Donations
Gift aid
Other income		 2023
£
157,787
8,575
1,175
167,537		 2022
£
334,133
3,888
40,426
378,447

3 Income from investments

Dividends
Deposit account interest
4
Expenditure on raising funds
Fundraising and publicity
Seeking donations, grants and legacies		 2023
£
345
11,856
12,201
2023
£
5,708		 2022
£
217
3,176
3,393
2022
£
4,214

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

5 Expenditure on charitable activities

Research salaries
Research expenses and lab fees
Grants to Institutions
Conference and Meeting
Event Expenses
Share of support and governance costs (see note 6)
Support
6
Support costs allocated to activities
Other resources expended
Management
Finance
Governance Cost		 2023
£
31,608
91,504
45,000
2,209
4,610
174,931
42,403
42,403
2023
£
22,114
2,420
17,869
42,403		 2022
£
70,237
73,619
4,715
15,039
0
163,610
34,683
34,683
2022
£
21,392
1,039
12,252
34,683

7 TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023.

Trustees' expenses

During the year £574.8 of expenses were paid to Dr Nathan relating to Membership expenses.

8 Employees

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Employment costs
Wages and salaries
Social security costs
Other pension costs
The average monthly number of employees during the year was as follows:
Secreterial/Administration:
There were no employees whose annual remuneration was more than £60,000.		 2023
£
14,000
329
233
14,562
2023
1		 2022
£
14,248
275
170
14,693
2022
1

9 Other Expenditure

Subscriptions
Travel and Subsistence
Wages
Staff recruitment
Pensions
Insurance
Staff Training
Telephone
Postage and stationery
Advertising
Computer expenses
Plant and machinery
Computer equipment
Website
Sundries
Bank charges
Accountancy and legal fees		 2023
£
3,112
-
14,000
329
233
574
275
76
448
1,526
882
64
217
186
192
2,420
17,869
42,403		 2022
£
2,690
134
14,248
275
170
284
52
65
300
2,199
564
85
326
-
-
1,039
12,252
34,683

10 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

11 Intangible fixed assets

11 Intangible fixed assets
Website
£
Cost
At 1 January 2023 -
Additions - separately acquired 1,858
At 31 December 2023 1,858
Amortisation and impairment
At 1 January 2023 -
Amortisation charged for the year 186
At 31 December 2023 186
Carrying amount
At 31 December 2023 1,672
At 31 December 2022 -
12 Tangible fixed assets
Plant and Computers Total
equipment
£ £ £
Cost
At 1 January 2023 254 652 906
At 31 December 2023 254 652 906
Depreciation and impairment
Depreciation charged in the year 64 217 281
At 31 December 2023 64 217 281
Carrying amount
At 31 December 2023 191 435 625
At 31 December 2022 254 652 906

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

13 Fixed asset investments

Listed
investments
£
Cost or valuation
At 1 January 2023 & 31 December 2023 6,469
Carrying amount
At 31 December 2023 6,469
At 31 December 2022 6,469

14 Debtors

Amounts falling due within one year:
Trade debtors
Prepayments and accrued income
Creditors: amounts falling due within one year
Social security and other taxes
Accruals and deferred income
Accrued expenses
Other creditors		 2023
£
-
4,196
4,196
2023
£
38
-
11,488
135
11,661		 2022
£
29,792
3,072
32,864
2022
£
317
4,500
18,036
27,002
49,855

15 Creditors: amounts falling due within one year

16 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

At
Unrestricted
Funds
Restricted funds		 1 January
2023
Incoming
resources
Resources
expended
£
£
£
686,780
116,090
(126,503)
541,995
63,648
(96,539)
1,228,775
179,738
223,042		 Transfers
Gains and
losses
At 31
December
2023
£
£
£
253,555
(30,002)
899,920
(253,555)
30,000
285,549
-
-
1,185,469		 Transfers
Gains and
losses
At 31
December
2023
£
£
£
253,555
(30,002)
899,920
(253,555)
30,000
285,549
-
-
1,185,469
1,185,469

Docusign Envelope ID: AB1D42D0-54D5-4733-B39F-E1A62D9F4D30

THE CANCER TREATMENT AND RESEARCH TRUST CIO

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

16
Unrestricted funds
Previous year:
At
Unrestricted
Funds
Restricted funds		 1 January
2022
Incoming
resources
Resources
expended
£
£
£
700,031
112,113
(125,364)
349,411
269,727
77,143
1,049,442
381,840
202,507		 (Continued)
Transfers
Gains and
losses
At 31
December
2022
£
£
£
-
-
686,780
-
-
541,995
-
-
1,228,775

17 Related party transactions

There were no related party transactions for the year ended 31 December 2023 or for 31 December 2022.